ESOT Virtual

Direct Access Request
Congress delegate:  Please request a direct access link here
Non-delegate:  It is also possible to purchase on-demand access, click here to create an account.
About this activity
Live session ended - Watch the Replay


Event Outline:
  • 2023-09-19 17:00:00 - 2023-09-19 17:10:00 - IMPACT OF DESENSITIZATION THERAPY WITH ISATUXIMAB ON HLA-SPECIFIC MEMORY B CELLS AND PLASMA CELLS IN HIGHLY SENSITIZED PATIENTS by Alba Torija
  • 2023-09-19 17:10:00 - 2023-09-19 17:20:00 - DARATUMUMAB DESENSITIZATION BEFORE KIDNEY TRANSPLANTATION – A PILOT STUDY by Marie Matignon
  • 2023-09-19 17:20:00 - 2023-09-19 17:30:00 - EARLY RESULTS OF ATTAIN (ITN090ST): DARATUMUMAB & BELATACEPT FOR HLA DESENSITIZATION IN KIDNEY TRANSPLANT CANDIDATES WITH 100% CPRA by Flavio Vincenti
  • 2023-09-19 17:30:00 - 2023-09-19 17:40:00 - A PILOT STUDY EVALUATING DUAL CO-STIMULATION BLOCKADE WITH DAZODALIBEP (HZN4920) AND BELATACEPT FOR PROPHYLAXIS OF KIDNEY ALLOGRAFT REJECTION by Flavio Vincenti
  • 2023-09-19 17:40:00 - 2023-09-19 17:50:00 - A PHASE I/IIA TRIAL OF AUTOLOGOUS REGULATORY T CELL THERAPY TOGETHER WITH DONOR BONE MARROW INFUSION IN KIDNEY TRANSPLANTATION by Thomas Wekerle
  • 2023-09-19 17:50:00 - 2023-09-19 18:00:00 - LONG-TERM OUTCOMES AFTER CONVERSION TO A BELATACEPT-BASED IMMUNOSUPPRESSION IN KIDNEY TRANSPLANT: A MATCHED COHORT STUDY by Gillian Divard
  • 2023-09-19 18:00:00 - 2023-09-19 18:10:00 - EFFECTIVENESS OF THE TREATMENT OF ANTIBODY MEDIATED REJECTION: A REAL-WORLD EVIDENCE STUDY by Gillian Divard
  • 2023-09-19 18:10:00 - 2023-09-19 18:20:00 - RESULTS OF THE TRIBUTE RADOMIZED TRIAL: TREATMENT WITH BORTEZOMIB OF LATE ANTIBODY-MEDIATED REJECTION DUE TO DE NOVO DSA by Renaud Snanoudj
Innovations in kidney immunosuppression
Speaker(s): Thomas Wekerle,  
Thomas Wekerle
Affiliations:
Marie-Benedicte Matignon,  
Marie-Benedicte Matignon
Affiliations:
Flavio Vincenti,  
Flavio Vincenti
Affiliations:
Torija Recasens Alba,  
Torija Recasens Alba
Affiliations:
Gillian Divard,  
Gillian Divard
Affiliations:
Renaud Snanoudj
Renaud Snanoudj
Affiliations:
ESOT Virtual. Presenters F. 09/19/2023; 398146;
all-in-one page photo
Thomas Wekerle
all-in-one page photo
Marie-Benedicte Matignon
all-in-one page photo
Flavio Vincenti
all-in-one page photo
Torija Recasens Alba
all-in-one page photo
Gillian Divard
all-in-one page photo
Renaud Snanoudj
About this activity
Live session ended - Watch the Replay


Event Outline:
  • 2023-09-19 17:00:00 - 2023-09-19 17:10:00 - IMPACT OF DESENSITIZATION THERAPY WITH ISATUXIMAB ON HLA-SPECIFIC MEMORY B CELLS AND PLASMA CELLS IN HIGHLY SENSITIZED PATIENTS by Alba Torija
  • 2023-09-19 17:10:00 - 2023-09-19 17:20:00 - DARATUMUMAB DESENSITIZATION BEFORE KIDNEY TRANSPLANTATION – A PILOT STUDY by Marie Matignon
  • 2023-09-19 17:20:00 - 2023-09-19 17:30:00 - EARLY RESULTS OF ATTAIN (ITN090ST): DARATUMUMAB & BELATACEPT FOR HLA DESENSITIZATION IN KIDNEY TRANSPLANT CANDIDATES WITH 100% CPRA by Flavio Vincenti
  • 2023-09-19 17:30:00 - 2023-09-19 17:40:00 - A PILOT STUDY EVALUATING DUAL CO-STIMULATION BLOCKADE WITH DAZODALIBEP (HZN4920) AND BELATACEPT FOR PROPHYLAXIS OF KIDNEY ALLOGRAFT REJECTION by Flavio Vincenti
  • 2023-09-19 17:40:00 - 2023-09-19 17:50:00 - A PHASE I/IIA TRIAL OF AUTOLOGOUS REGULATORY T CELL THERAPY TOGETHER WITH DONOR BONE MARROW INFUSION IN KIDNEY TRANSPLANTATION by Thomas Wekerle
  • 2023-09-19 17:50:00 - 2023-09-19 18:00:00 - LONG-TERM OUTCOMES AFTER CONVERSION TO A BELATACEPT-BASED IMMUNOSUPPRESSION IN KIDNEY TRANSPLANT: A MATCHED COHORT STUDY by Gillian Divard
  • 2023-09-19 18:00:00 - 2023-09-19 18:10:00 - EFFECTIVENESS OF THE TREATMENT OF ANTIBODY MEDIATED REJECTION: A REAL-WORLD EVIDENCE STUDY by Gillian Divard
  • 2023-09-19 18:10:00 - 2023-09-19 18:20:00 - RESULTS OF THE TRIBUTE RADOMIZED TRIAL: TREATMENT WITH BORTEZOMIB OF LATE ANTIBODY-MEDIATED REJECTION DUE TO DE NOVO DSA by Renaud Snanoudj

What's new

We're thrilled to share the official Congress Review, capturing the most exciting moments and thrilling milestones from a truly unforgettable event. Take a look at: The congress in numbers | Highlights from the Opening Session | Breakthroughs from the Scientific Programme | A celebration of our award winners | A close look at the Legacy Project | And much more...

About Us

The European Society for Organ Transplantation (ESOT) was founded 40 years ago and is dedicated to the pursuit of excellence in organ transplantation. Facilitating a wealth of international clinical trials and research collaborations over the years, ESOT remains committed to its primary aim of improving patient outcomes in transplantation.
2025 ©
The European Society for Organ Transplantation
USER TERMS AND CONDITIONS / PRIVACY POLICY
(Amended according to GDPR)

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies